The North America Glycated Albumin Assay Market would witness market growth of 7.7% CAGR during the forecast period (2023-2030).
The glycated albumin assay test can assist in identifying a person's risk for developing complications from the condition and how effectively they manage their diabetes. It is the fructosamine that has been more heavily glycated. It is assessed using a simple and fast enzymatic approach. Glycated albumin testing offers an early and precise evaluation of glycemic management. Glycated albumin readings, instead of glycated hemoglobin, measure long-term glucose levels & show changes in blood sugar levels over the previous two to three weeks. As a result, healthcare providers may optimize diabetes management and lower the risk of complications. This enables rapid intervention and modification of treatment strategies.
The accuracy and dependability of glycated albumin readings will be further enhanced by developing novel technologies & techniques, such as enzymatic and immunoassay-based approaches. Furthermore, incorporating glycated albumin testing with point-of-care devices, digital health platforms, and other related technologies would improve accessibility and practicality for patients and healthcare professionals. The market holds significant promise for improving diabetes management, directing treatment choices, and lowering the risk of complications connected to diabetes as the need for personalized medicine and customized therapies increases. With technological developments and rising clinical usage expected to transform glycemic monitoring and enhance patient outcomes, the future of the market is optimistic.
The 2020 update to the National Diabetes Statistics Report shows that, according to rough estimates for 2018, 10.5% of the US population, or 34.2 million persons of all ages, has diabetes. Thirteen percent of all US adults, or 34.1 million adults over 18, had diabetes. There were 7.3 million adults (18 years and older) who did not know they had diabetes or did not disclose it. These adults met the laboratory criteria for diabetes. 2.8% of US adults and 21.4% of US adults with diabetes are represented by this percentage. With advancing years, the proportion of persons with diabetes rose, reaching 26.8% among those 65 and older. The market is predicted to expand in this region due to the increased prevalence of diabetes.
The US market dominated the North America Glycated Albumin Assay Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $106,249.1 Thousands by 2030. The Canada market is experiencing a CAGR of 10.1% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 9.2% during (2023 - 2030).
Based on Application, the market is segmented into Type 2 Diabetes, Type 1 Diabetes, and Prediabetes. Based on End User, the market is segmented into Hospitals & Diabetic Care Center, Diagnostic Laboratory, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Glycated Albumin Assay Market is Projected to reach USD 384.5 Million by 2030, at a CAGR of 8.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Asahi Kasei Pharma Corporation (Asahi Kasei Corporation), EKF Diagnostics Holdings plc, Weldon Biotech India Private Limited, Hzymes Biotechnology Co., Ltd., Beijing Strong Biotechnologies, Inc., Diazyme Laboratories, Inc. (General Atomics), Abbexa Limited, Biomatik Corporation, Abnova Corporation and Geno Technology, Inc.
By Application
By End User
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
